BioSpace News Archive

Fresenius Kabi announced it has introduced Plerixafor Injection, a generic equivalent to Mozobil®, available immediately in the United States in a 24 mg per 1.2 mL single dose vial.

Ainos, Inc. announced that it had signed an agreement with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co. to co-develop a volatile organic compound sensing platform.

Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery systems that provide painless and precise injections, today announces, positive reimbursement was received from three commercial payers for the use of the CompuFlo® Epidural System for patients who were involved in motor vehicle accidents.

Omeros Corporation today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2023.

TFF Pharmaceuticals, Inc. today announced that it management will host a conference call to discuss the financial results for the second quarter of 2023 and provide an update on recent corporate and clinical developments on Tuesday, August 15, 2023.

China Pharma Holdings, Inc. announced that its wholly-owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd. has received the “Drug Supplementary Application Approval Notice” for its candesartan tablets by National Medical Products Administration of China, indicating that the Company’s candesartan tablets have passed the quality and efficacy consistency evaluation of generic drugs.

Sunbird Bio, a biotechnology company developing proprietary protein-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, announced that they have completed a merger with Glympse Bio to accelerate development of the companies’ protein-based diagnostic platforms.

The first study reports a new approach to prevent hearing loss induced by the widely used chemotherapeutic drug “cisplatin”. The article was available online in April 2023 and published in Volume 13, Issue 6 in June 2023.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced completed enrollment for the multi-site observational study, HOPE PMR (Portable MRI for Children with Neurological Injury—A Pilot Study using Hydrocephalus as an Index Condition).

Mitsubishi Tanabe Pharma Canada publicly announced its collaboration with the Canadian Neuromuscular Disease Registry, an independent, academic registry based out of the University of Calgary, on the first Canadian real-world evidence generation study1 of RADICAVA® IV for the treatment of people with amyotrophic lateral sclerosis.